---
Title: "Official source checks for the sourcing-layer draft"
Author: "Codex, original research paraphrases"
Reference: "Official URLs linked in this source capture"
ContentType:
  - "markdown"
Created: 2026-10-27
Processed: true
tags:
  - "source"
---

# Official Source Checks

These are original paraphrases of official material checked on 2026-10-27, for planning rather than medical conclusions. They establish source roles; they do not establish a functioning connector or validate a treatment claim. Firecrawl CLI reported unauthenticated; the available web tool performed these checks.

## Literature

[PubMed Help](https://pubmed.ncbi.nlm.nih.gov/help/) explains that records include citations and, when available, abstracts. Full text is linked to other sources, including publishers and PMC. Publication types and dates can assist search. Plan implication: PubMed is a discovery/index layer; retrieved metadata alone cannot establish a current recommendation. Check article type, issuer, scope, version and actual accessible text. [NCBI developer APIs](https://www.ncbi.nlm.nih.gov/home/develop/api/) identifies E-utilities as the programmatic interface for Entrez databases including PubMed.

## Trials And Organizations

[NLM's API v2 announcement](https://www.nlm.nih.gov/pubs/techbull/ma24/ma24_clinicaltrials_api.html) documents the ClinicalTrials.gov REST/OpenAPI interface. [Current ClinicalTrials.gov common questions](https://clinicaltrials.gov/find-studies/for-patients/common-questions) describes study information as supplied by the person or organization responsible for a study. [NLM's record-display explanation](https://www.nlm.nih.gov/pubs/techbull/mj24/mj24_Clinical_Trials_Study_Record_Modernization.html) distinguishes supplied registration fields and missing information. [NLM's QC explanation](https://www.nlm.nih.gov/pubs/techbull/jf20/jf20_clinicaltrials_qc.html) states that listing does not constitute NIH endorsement. Plan implication: use structured registration/results fields, with missing values and source dates visible; stage, sponsor and results availability are different facts from efficacy or approval.

The browser extraction of the ClinicalTrials.gov API overview and policy pages returned only the site shell. Do not claim their field reference was inspected in full. The exact adapter field paths must be verified against a real API response and current schema during implementation.

## Regulation

[About Drugs@FDA](https://www.fda.gov/drugs/drug-approvals-and-databases/about-drugsfda) describes covered human drug products and approval-related documents. [FDA's drug information directory](https://www.fda.gov/drugs/information-consumers-and-patients-drugs/find-information-about-drug) directs users to approval history and labeling. [The FDA online label repository](https://labels.fda.gov/) warns that submitted listing text can differ from approved labeling. Plan implication: retrieve product- and indication-specific approval evidence. Neither a generic listing nor a missing search match establishes approval/nonapproval. Devices and other products outside the chosen drug connector need separate coverage.

## Candidate Condition Guideline

[ADA's official Standards of Care page](https://professional.diabetes.org/standards-of-care) points to its 2026 recommendations, describes annual updates and possible interim online changes, and lists the pharmacologic treatment section. Plan implication: adult type 2 diabetes is a candidate first condition; bind a supported-condition entry to checked relevant sections and versions. Publisher landing-page visibility is established; successful application extraction, applicable recommendation selection and permission to retain full text remain implementation checks. This source is an addition proposed by the drafting agent, not an institution selected by the interviewer.

## CDC

[CDC's About page](https://www.cdc.gov/about/index.html) describes health data, guidance and prevention functions. Plan implication: use CDC selectively for relevant public-health context or a specific applicable guideline, rather than as a universal treatment or development-pipeline source. No CDC connector is required for the proposed first slice.
